Moleculin's Annamycin Shows Promising Cardiac Safety Data at ASCO 2026 — Moleculin Biotech, Inc.

Event summary

Moleculin's abstract on Annamycin's cardiac safety data accepted for poster presentation at the 2026 ASCO Annual Meeting.
Pooled analysis of 90 patients across five trials showed no statistically significant change in left ventricular ejection fraction (LVEF).
Median cumulative Annamycin dose of 660 mg/m2 exceeded conventional lifetime anthracycline limits without observed cardiotoxicity.
Annamycin demonstrated 50% complete remission rate and 60% composite complete remission rate in a Phase 1b/2 study for AML.
MIRACLE Phase 3 trial for Annamycin in AML is ongoing, with FDA input de-risking the development pathway.

The big picture

Moleculin's Annamycin represents a potential breakthrough in anthracycline therapy, addressing the critical limitation of cardiotoxicity. The positive cardiac safety data presented at ASCO 2026 strengthens the drug's profile as a differentiated treatment option for relapsed or refractory acute myeloid leukemia (AML). The ongoing MIRACLE Phase 3 trial, with FDA input, positions Moleculin to potentially secure regulatory approval, though the company's ability to secure financing remains a key risk factor.

What we're watching

Clinical Validation: Whether the positive cardiac safety data will accelerate regulatory approval for Annamycin.
Market Differentiation: How Annamycin's lack of cardiotoxicity positions it against traditional anthracyclines in the AML market.
Execution Risk: The pace at which Moleculin can secure additional financing to complete the MIRACLE Phase 3 trial.